Friday, 21 Jul 2017

You are here

Spinal Manipulation Equal to NSAIDS for Acute Low Back Pain

JAMA has published a review of 15 RCTs (1711 patients) analyzing the role of spinal manipulation therapy in patients with acute low back pain. The authors found modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms.

Back pain is among the most common symptoms prompting patients to seek care. Lifetime prevalence estimates of low back pain exceed 50 percent. Treatments for acute back pain include analgesics, muscle relaxants, exercises, physical therapy, heat, spinal manipulative therapy (SMT) and others, with none established as superior to others. Paul G. Shekelle, M.D., Ph.D., of the West Los Angeles Veterans Affairs Medical Center, Los Angeles, and colleagues conducted a review and meta-analysis of previous studies to assess the effectiveness and harms associated with spinal manipulation compared with other nonmanipulative therapies for adults with acute (six weeks or less) low back pain.

Of 26 eligible randomized clinical trials (RCTs) identified, 15 RCTs (1,711 patients) provided moderate-quality evidence that SMT has a statistically significant association with improvements in pain. Twelve RCTs (1,381 patients) produced moderate-quality evidence that SMT has a statistically significant association with improvements in function. No RCT reported any serious adverse event. Minor transient adverse events such as increased pain, muscle stiffness, and headache were reported 50 percent to 67 percent of the time in large case series of patients treated with SMT. Heterogeneity (differences) in study results was large, and was not explained by type of clinician performing SMT, type of manipulation, study quality, or whether SMT was given alone or as part of a package of therapies.

The authors write that the size of the benefit of SMT for acute low back pain is about the same as the benefit from nonsteroidal anti-inflammatory drugs, according to the Cochrane review on this topic.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

No surprise. Many of these patients will improve regardless of treatment or lack thereof UNLESS there are psychosocial "drivers". Time and placebo remain effective therapies unless the patient's perception of the meaning of the pain results in pain behavior. Many people live paycheck to paycheck and need a "quick fix" to get back to their life responsibilities and obligations. Activity modification or decreased income are not options for such patients.

More Like This

FDA Requests Removal of OPANA-ER from the Market

The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.

A March 2017 advisory committee concluded that Opana ER, is not safe, and many have called for its removal.

Opana ER is twice as potent as oxycodone and has a high abuse potential when crushed and taken for a massive high effect by addicts.  

Ohio Sues Five Pharma Companies Over Opioid Epidemic

Ohio is suing five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers that has resulted in the current opioid epidemic. The Attorney General of Ohio, Mike DeWine, wants to hold big Pharma responsible for a deadly and costly opioid crisis.

Non-Prescribed Opioid Abuse by Young Adults

Journal of Addiction Medicine reported that young adults often are "self-medicated" to manage pain.

Lyrica Fails in Sciatica Pain

Lyrica (pregabalin) was first approved in 2004 and since has been studied and approved for use in neuropathic pain (associated with diabetic neuropathy), postherpetic neuralgia, partial onset seizures, fibromyalgia and neuropathic pain with spinal cord injury. It is often used to manage chronic pain and neuropathic pain outside these indications.

Limited Benefits with Intra-Discal Steroid Injections for Back Pain

A a randomized trial published in Annals of Internal Medicine shows that intradiscal glucocorticoid injection has limited (1 month) efficacy in treating low back pain (LBP) associated with active discopathy, yet decreased over time.